Share
Services
Biopharma ‚Meet the Management‘ Presentation
January 12, 2026
San Francisco, USA
January 12 – 14, 2026
FY/25: Strong organic revenue and excellent Core EPS growth
1 Before special items; 2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation; 3 Growth rate adjusted for Argentina hyperinflation; 4 Excluding Fresenius Medical Care
View the full FY/25 update in the Financial Results section.
Read more about our company strategy!
May 06, 2026 - 01:30 pm
Bad Homburg, Germany
The Fresenius Annual Report 2025 is available as an online-version with enhanced functionality and as a PDF.
Over the past three years, we have successfully implemented our #FutureFresenius strategy and created a new Fresenius that is innovative, relevant, resilient, and adaptable. Highlights include a message from CEO Michael Sen, success stories from Fresenius Kabi and Fresenius Helios, our first ESRS-compliant sustainability statement, and financial performance insights.
Sustainability is a part of Fresenius’ corporate strategy. Our Sustainability Statement shows how we address environmental, social, and governance topics and manage the associated impacts, risks, and opportunities.
"2025 was a pivotal year for Fresenius. With disciplined execution of our #FutureFresenius strategy and a strong performance from Team Fresenius, we met our upgraded full-year guidance by delivering another quarter of competitive growth [...]. 2025 capped a year of continued momentum across the Company: We further strengthened the balance sheet, and upgraded our guidance, while preparing the business through targeted investment for the next phase of growth. All of this leads to a proposed dividend of €1.05 per share, underscoring our commitment to creating shareholder value [...]. With #FutureFresenius we have transformed our Company, positioning ourselves to deliver future success in a new world order. Looking ahead, we enter 2026 with strong foundations and clear priorities [...]."
Michael Sen, Chairman of the Management Board
Financial Results
FY 2025: REJUVENATE in Action – Delivering accelerated performance for long-term value creation!
Outlook
New guidance metric established: Fresenius Outlook 2026 at a glance.
Financial Reports
Discover Fresenius financial reports and presentations here!
Goals & Strategy
#FutureFresenius is clearly paying-off. Find out more about our company's strategy!
Open dialogue is valuable for us.
You can submit your feedback quickly and easily using the link below (anonymously if you prefer).
You will be redirected to QuantiFire which conducts this survey in own controllership.
Brief News
Today, Fresenius has launched the AI-powered assistant – “AskFRE” – on its Investor Relations (IR) website, marking an important step in advancing its digital capital markets communications. The solution is a joint initiative of the Fresenius AI Center of Excellence and the Investor Relations team.With AskFRE, visitors can now interact with an integrated AI chatbot that provides direct answers to capital market-relevant information. This includes financial results, company updates and other IR content – based exclusively on publicly available Fresenius disclosures.In an increasingly fast-paced and data-driven environment, digital investor relations play a key role in delivering timely, transparent and stakeholder-focused communication. AskFRE supports this ambition by enabling more intuitive access to financial information and tailored user interactions, while reinforcing the consistency and accessibility of Fresenius’ disclosures.With AskFRE, Fresenius underscores its commitment to advancing a best in class digital investor relations experience.AskFRE is now available: https://www.fresenius.com/AskFRE-Your-IR-Assistant
May 26, 2026 · Fresenius
Brief News
Fresenius announced today that the Company's Q1 2026 Aide Memoire is now available on the Company's Investor Relations website.As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q1 2026 financial results will be published on May 6, 2026.
April 17, 2026 · Fresenius
Brief News
Today, Fresenius published its 2025 Annual Report. As announced in late February 2026, 2025 marked another strong year of performance and the launch of the current phase of the #FutureFresenius strategy: Rejuvenate. Despite headwinds, the healthcare group achieved its outlook, which was raised twice during the year. Group revenue before special items rose to €22.6 billion, with organic growth of 7%, while constant currency Core EPS (excluding FMC) increased by 12%. “Over the past three years, we have successfully implemented our #FutureFresenius strategy and created a new Fresenius that is innovative, relevant, resilient, and adaptable. At the same time, we have significantly bolstered our company’s economic strength. We aim to build on this strong foundation,” said Michael Sen, Chairman of the Management Board of Fresenius. The 2025 Annual Report demonstrates how Fresenius is creating sustainable value for all stakeholders by executing its #FutureFresenius strategy. It includes the Sustainability Statement in accordance with the European Sustainability Reporting Standards (ESRS), and is available as a PDF and as an interactive online version in German and English. The online report features additional business stories and includes a video statement from CEO Michael Sen.
March 25, 2026 · Fresenius
Brief News
Fresenius Kabi, an operating company of Fresenius, has entered a first-of-its-kind partnership with U.S. manufacturer Phlow Corp. to establish a fully domestic, end-to-end supply chain for Epinephrine Injection, USP — an FDA designated essential medicine frequently at risk of shortage in the United States. Under the collaboration, Phlow will produce the U.S.-based API, while Fresenius Kabi manufactures the finished doses for hospitals and clinics across the country. With this initiative, Fresenius advances its local-for-local manufacturing strategy and supports national efforts to strengthen pharmaceutical security. The partnership reinforces the ambitions of #FutureFresenius as it expands Fresenius’ role as a leading global provider of lifesaving therapies, advancing resilient manufacturing that improves patient care and health-system stability. Pending regulatory approvals, epinephrine produced through this collaboration could be available to U.S. hospitals in 2027.
February 09, 2026 · Fresenius Kabi
Brief News
Fresenius has entered into a strategic development agreement with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next generation treatments. Under the agreement, operating company Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics’ proprietary cell selection technology into its Cue® Cell Processing System. The combined solution aims to isolate high purity T cells in less than two hours, helping therapy developers streamline processes and accelerate development. The collaboration is in line with Fresenius’ #FutureFresenius strategy to focus on high value healthcare platforms, strengthen core technologies, and improve patient access through operational excellence and innovation. By enabling more automated, robust, and scalable cell therapy manufacturing, Fresenius Kabi and TQ Therapeutics aim to support the broader adoption of cell and gene therapies, including applications closer to the point of care.
January 14, 2026 · Fresenius Kabi
Effective immediately, Katrin Kerner (44) and Christian Wagner (39) will assume joint leadership of Group Communications at Fresenius. Both will assume the role on an interim basis and in addition to their current responsibilities as Head of CEO Relations and Head of Board Office. They will report directly to Fresenius CEO Michael Sen and succeed Anke Schmidt, who has led the communications function since June 2025 and has decided to leave the company at her own request. “On behalf of the Management Board, I would like to express my sincere thanks to Anke Schmidt for her work and commitment. She has made an important contribution in a short period of time. We wish her all the best for her future endeavors”, says Michael Sen, CEO of Fresenius. “I am very pleased that Katrin Kerner and Christian Wagner will jointly assume this responsibility as a leadership team. Both have a deep understanding of the healthcare industry and are already actively shaping the strategic and cultural transformation of our company through #FutureFresenius. With their extensive experience in communications, finance, and corporate transformations at DAX-listed companies, they will further develop the communications function at Fresenius and continue to strengthen our brand.” Katrin Kerner has been with Fresenius since 2023 and has served as Head of CEO Relations since 2024. In this role, she prepares CEO briefings, coordinates strategic company positions, and manages global partnerships. Before joining Fresenius, she held several leadership positions in communications functions at Siemens, Siemens Healthcare (today Siemens Healthineers), and Siemens Energy, including Head of Employee Communications at Siemens and Head of Executive Messages at Siemens Energy. During this time, she was actively involved in the IPO of Siemens Healthineers and the spin-off of Siemens Energy. Katrin Kerner studied Economics at the Friedrich-Alexander University Erlangen-Nürnberg and International Management at the Turku School of Economics in Finland. Christian Wagner joined Fresenius in 2017, became Head of Corporate Finance in 2019, and has served as Head of Board Office since 2023. In this function, he plays a key role in steering and advancing Fresenius’s strategic direction. He is also responsible for Corporate Security. Before joining Fresenius, Christian Wagner worked in investment banking at Berenberg and at a subsidiary of Deutsche Bahn. He studied Finance at Goethe University Frankfurt and the Institut Supérieur du Commerce (ISC) in Paris, France.
November 14, 2025 · Fresenius
Brief News
The German Association for Financial Analysis and Asset Management (DVFA) Scorecard for Corporate Governance serves as an important benchmark for assessing governance standards among DAX 40 companies in Germany. Fresenius has reached 2nd place in this year’s ranking – a significant leap from last year and thus the largest climb of all companies evaluated. This recognition reflects the significant progress made to further strengthen the company’s governance structures as part of the #FutureFresenius strategy.
November 14, 2025 · Fresenius
Follow Fresenius Investor Relations for expert insights and latest news that contribute to the Fresenius equity story, and exclusive content from our team. Join our growing community and be part of the conversation!
mAbxience, a Fresenius entity, has entered into a collaboration with HP Inc. to develop an artificial intelligence (AI) solution aimed at making biomanufacturing more efficient and reliable.
The joint project uses AI and digital-twin technology to model and optimize key steps in the production of monoclonal antibodies and biosimilars. By simulating critical cell-culture parameters and predicting process outcomes, the system is designed to support more consistent yields, faster development cycles, and better control of large-scale manufacturing environments. This is a showcase of Fresenius’ pathway in leveraging AI and digital solutions, from production and supply-chain to care delivery, improving treatment quality, and expanding access to state-of-the-art therapies.
Both partners view the technology as a significant step toward more data-driven and tightly managed bioproduction. The prototype, developed with real manufacturing data and validated in an industrial setting, enables teams to test scenarios virtually before applying them on the shop floor.
This initiative is the first project under a broader strategic framework between HP and mAbxience at its manufacturing facility in Leon, Spain, and has the potential to be rolled out across additional sites. It represents another milestone in advancing Fresenius’ (Bio)Pharma platform and supports the goals of #FutureFresenius.
Fresenius in Spain
The global healthcare company Fresenius is deeply rooted in Spain. With Quirónsalud, the country’s leading hospital operator, and Fresenius Kabi, offering essential medicines and technologies for critically and chronically ill patients, the company makes a decisive difference in the life-quality of Spanish citizens. With the majority acquisition of mAbxience in 2022, Fresenius created a dedicated and vertically integrated biosimilars development and manufacturing platform. In line with its #FutureFresenius strategy, the company is further scaling in (Bio)Pharma to deliver simplification and drive efficiencies, underscoring its commitment to offering accessible, innovative, and high-quality healthcare solutions.
mAbxience, a Fresenius entity, has entered into a collaboration with HP Inc. to develop an artificial intelligence (AI) solution aimed at making biomanufacturing more efficient and reliable.
The joint project uses AI and digital-twin technology to model and optimize key steps in the production of monoclonal antibodies and biosimilars. By simulating critical cell-culture parameters and predicting process outcomes, the system is designed to support more consistent yields, faster development cycles, and better control of large-scale manufacturing environments. This is a showcase of Fresenius’ pathway in leveraging AI and digital solutions, from production and supply-chain to care delivery, improving treatment quality, and expanding access to state-of-the-art therapies.
Both partners view the technology as a significant step toward more data-driven and tightly managed bioproduction. The prototype, developed with real manufacturing data and validated in an industrial setting, enables teams to test scenarios virtually before applying them on the shop floor.
This initiative is the first project under a broader strategic framework between HP and mAbxience at its manufacturing facility in Leon, Spain, and has the potential to be rolled out across additional sites. It represents another milestone in advancing Fresenius’ (Bio)Pharma platform and supports the goals of #FutureFresenius.
Fresenius in Spain
The global healthcare company Fresenius is deeply rooted in Spain. With Quirónsalud, the country’s leading hospital operator, and Fresenius Kabi, offering essential medicines and technologies for critically and chronically ill patients, the company makes a decisive difference in the life-quality of Spanish citizens. With the majority acquisition of mAbxience in 2022, Fresenius created a dedicated and vertically integrated biosimilars development and manufacturing platform. In line with its #FutureFresenius strategy, the company is further scaling in (Bio)Pharma to deliver simplification and drive efficiencies, underscoring its commitment to offering accessible, innovative, and high-quality healthcare solutions.
Michael Sen became CEO (Chairman of the Management Board) of Fresenius on October 1, 2022. He joined Fresenius in April 2021 as CEO of Fresenius Kabi. Before joining Fresenius Kabi, Michael Sen was a member of the Management Board of Siemens AG, where he was responsible for the healthcare business Siemens Healthineers and for Siemens’ energy business. Prior to that, he was Chief Financial Officer of E.ON SE. At the start of his professional career, Michael Sen completed an apprenticeship at Siemens in Berlin and then studied business administration at the Technical University of Berlin.
Pierluigi Antonelli joined the Management Board of Fresenius in March 2023 with responsibility for Fresenius Kabi. In his previous role since 2019, he was the CEO of Angelini Pharma, a company of the Italian Angelini Group specializing in brain health and consumer health. Prior to that, he held senior leadership positions at Novartis Oncology, Sandoz, Merck & Co. and Bristol Myers Squibb in the United States and across Europe.
Sara Hennicken was appointed CFO of Fresenius as of September 1, 2022. She joined the Group in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Previously, she spent 14 years in investment banking, including nine years at Deutsche Bank, lastly as Managing Director and Senior Client Executive in Corporate Finance Coverage before moving to Fresenius. Between 2005 and 2010 she worked for Citigroup in Frankfurt and London. Sara Hennicken studied economics in Germany and in the United States.
Robert Möller joined the Management Board of Fresenius in September 2023 with responsibility for Fresenius Helios. Robert Möller has been CEO of Helios Kliniken GmbH since 2022. He joined Helios in 2014, where he held the position of Clinic Managing Director at Helios Hanseklinikum Stralsund until 2017. After a short time away, he returned to Helios in 2019 and took over the management of various regions. Möller studied human medicine at the University of Hamburg and practiced as a specialist for internal medicine. After various medical positions and a part-time master's degree in health care management, he switched to hospital management while continuing to work as a physician.
Michael Moser joined the Management Board of Fresenius in July 2023. He is responsible for Legal, Compliance, Risk Management, Sustainability, Human Resources, Corporate Audit and transformation of the Vamed businesses. After starting his career at Baker McKenzie, he joined E.ON SE in 2008. During this time, he inter alia became member of the Management Board of the stock listed company ENEVA in Brazil, steered the listing of Uniper and served as Deputy CEO and CFO of Enerjisa, the stock listed leading energy company in Turkey. He has received university degrees in law and business economics in Germany, USA, UK, Switzerland and China.
Contact
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
board@fresenius.com
Operational implementation of the Human Rights Program is ensured through Group-wide governance and clear responsibilities within the business segments and at Group level. The Management Board oversees our Group-wide Human Rights Program. The Group function Risk & Integrity reports directly to the Board member responsible for Sustainability.
Within this Group function, the Group Human Rights Office is responsible for the Group-wide human rights due diligence approach, such as the Human Rights Risk Assessment methodology. It supports the business segments in implementing requirements that serve to fulfill their human rights due diligence obligations. In addition, the Group Human Rights Office monitors relevant legal and regulatory developments. It further chairs the Human Rights Council and exchanges with the Group's Risk Steering Committee.
Each business segment has appointed a Human Rights Function. This Human Rights Function is responsible for the operational implementation of the Group-wide human rights strategy within its own business segment. It reports to the Group Human Rights Office and its respective Board or Management.
We have appointed risk owners for relevant departments. As subject matter experts, the risk owners are responsible for appropriate risk management and the implementation of risk analyses in their area of responsibility – for example in Human Resources, Procurement, or Occupational Health and Safety.
The risk owners provide functional expertise for the risk evaluation and identification, analysis, prioritization, and management of risks. These tasks are fulfilled in collaboration with the respective risk management functions as well as with the business segment’s Human Rights Function to whom information is reported. This cross-functional exchange ensures a four-eye principle.
We have set up a Human Rights Council to promote the exchange of information on current human-rights-related initiatives and topics within the Fresenius Group. It is made up of representatives from various functions, such as Compliance, Sustainability, Communication, and Procurement, as well as the Human Rights Functions and the Group Human Rights Office.
The Human Rights Council meets quarterly. The meetings focus on the further implementation of the Human Rights Program, the ongoing development of reporting structures as well as increasing transparency along our value chains.
Explore our interviews:
Fresenius Kabi is committed to respecting human rights across its global supply chains. Marco Kraemer, Director Supplier Quality Management & Human Rights Function, explains how business partners are engaged through binding standards and how industry initiatives for audit-sharing and best practices are leveraged – enhancing transparency, efficiency, and sustainable responsibility.
Helios Germany firmly embeds human rights into daily hospital operations. Tim Schleifenecker, Head of Corporate Governance, explains how binding policies, training, and the internal control system ensure employees and partners comply with human rights standards. These synergies enhance transparency, risk management, and a culture of responsibility.
Fresenius Helios embeds human rights across its hospital supply chain. Imke Wagenknecht, Sustainability Manager for Procurement and Logistics, shows how procurement enforces a binding supplier Code of Conduct, and uses risk-based analyses to tackle potential risks – building transparency, trust, and long-term resilience.
Fresenius strengthens human rights across its business areas. Sabine Schmitt and Lisa Armbruster explain how potential risks such as workplace safety or discrimination are identified through regular analyses and addressed via targeted prevention.
The Group Human Rights Office supports the business segments and monitors their activities for implementing human rights due diligence. The appropriateness and effectiveness of these are monitored via the implemented processes, measures and corresponding documentation.
In addition, alongside the review by the Group Human Rights Office, internal controls are an integral part of Fresenius’ risk management. The internal control system (ICS) consists of a comprehensive set of internal controls and complementary processes. The results are incorporated into the regular review of the adequacy and effectiveness of our Human Rights Program.
We are continuously working to develop and expand the processes and procedures of our Human Rights Program. In addition, we test existing procedures as well as new approaches and concepts together with various participants. These include, for example, official advice centers for the implementation of human rights due diligence and specialized consulting firms.
Human Rights at Fresenius
Our Human Rights ProgramFurther Information
Risk Assessment & Impact Preventive & Remedial Action Grievance Procedure & HandlingContact
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
humanrights@fresenius.com
Human Rights Program
Our Human Rights Program Risk Assessment & Impact Preventive & Remedial Action Grievance Procedure & HandlingWhistleblowing system
Reports on possible human rights or other types of compliance violations can be reported around the clock, either anonymously or by name, via our whistleblower system*:
Phone number: +49 (0) 800 181 1338*
https://freseniusgroup.ethicspoint.com
More infos about our grievance mechanism
*The prices of your mobile or landline contract apply
The reporting on the respect for human rights for the year 2024 and following can be found in our Sustainability Report (CSRD Report). Further information on Fresenius' human rights program is available here: fresenius.com/en/human-rights
Fresenius announced today the launch of its denosumab biosimilars, Conexxence®1 (denosumab) and Bomyntra®2 (denosumab), in Europe.
These biosimilars received approval from the European Commission in July 2025 for all indications of the reference products Prolia®3 (denosumab) and Xgeva®4 (denosumab), respectively.
“Being the first biosimilar company with a pre-filled syringe for the denosumab oncology indication in Europe, showcases our commitment to offering new treatment options that support patient care and affordability across Europe,” said Dr. Sang Jin Pak, President Biopharma.
This milestone marks the next step in the company’s ambition to drive accessibility to high-quality biosimilar therapies, with multiple molecules in early and late-stage development. By continuing its successful track record in the biosimilars space, Fresenius further strengthens its (Bio)Pharma platform, a key pillar of the #FutureFresenius strategy.
1. Conexxence® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
2. Bomyntra® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
3. Prolia® is a registered trademarks of Amgen Inc.
4. Xgeva® is a registered trademarks of Amgen Inc.
